PHAR · Pharming Group N.V.
$11.92
+0.17% last session
End-of-day data · close of 2026-10-27
Market cap
$1B
Enterprise value
$1B
Trailing P/E
91.5
Forward P/E
30.9
Dividend yield
0.0%
Beta
0.07
Avg volume
0M
Employees
0K
Daily Change %
0.17%
5 Days Change
11.53%
10 Days Change
27.14%
30 Days Change
13.77%
60 Days Change
1.71%
Month to Day Change
19.60%
Year to Day Change
-32.65%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PHAR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-22
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | HC Wainwright & Co. | Reiterates | Buy | $37.00 |
| 2026-09-14 | HC Wainwright & Co. | Reiterates | Buy | $37.00 |
| 2026-08-03 | Canaccord Genuity | Maintains | Buy | $37.00 → $38.00 |
| 2026-04-10 | Canaccord Genuity | Initiates | Buy | $0.00 → $37.00 |
| 2026-03-24 | HC Wainwright & Co. | Reiterates | Buy | $37.00 |
| 2026-03-13 | Oppenheimer | Reiterates | Outperform | $42.00 → $41.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-27
- neutral: RSI (14): RSI is 69 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 11.5% above the 50-day MA ($10.69).
- bearish: Price vs 200-day MA: Trading 14.1% below the 200-day MA ($13.88).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.33) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($9.11) and high ($21.18).
PHAR Price Chart
Loading chart for PHAR…
Fundamentals
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.